Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

Core Viewpoint - Aeterna Zentaris Inc. and Ceapro Inc. have successfully approved an all-stock merger of equals transaction, which is expected to create a sustainable biopharmaceutical business positioned to deliver value to shareholders [1][3]. Voting Results - Aeterna shareholders voted in favor of the transaction with 78.97% supporting the issuance resolution and 79.71% approving the increase in the number of directors [2]. - Ceapro shareholders also approved the arrangement resolution with 67.23% voting in favor [3]. Leadership Statements - Aeterna's Chair, Carolyn Egbert, expressed gratitude for shareholder support, emphasizing the transaction's potential to create long-term value [3]. - Ceapro's Chairman, Ronnie Miller, highlighted the transaction as a crucial step towards completion [3]. Transaction Details - The merger is subject to customary closing conditions, including Alberta court approval and stock exchange approvals, with an expected closing in the second quarter of 2024 [1][3]. - A new name for the combined company will be announced for shareholder approval at the first annual meeting [3]. Company Profiles - Aeterna Zentaris is focused on developing a diversified portfolio of pharmaceutical and diagnostic products, with its lead product being macimorelin, approved for diagnosing adult growth hormone deficiency [5][6]. - Ceapro Inc. specializes in proprietary extraction technology for producing active ingredients from oats and other renewable resources, targeting cosmeceutical, nutraceutical, and therapeutic applications [7].